U.S. Pharmacy Benefit Management Market (By Business Model: Standalone PBM, Health Insurance Providers; By Service: Specialty Pharmacy, Retail Pharmacy; By End-user: Commercial, Federal) - Regional Outlook and Forecast 2024 to 2033
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: U.S. Pharmacy Benefit Management Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. U.S. Pharmacy Benefit Management Market, by Business Model, 2024-2033
8.1.1 Standalone PBM
8.1.1.1. Market Revenue and Forecast (2021-2033)
8.1.2. Health Insurance Providers
8.1.2.1. Market Revenue and Forecast (2021-2033)
9.1. U.S. Pharmacy Benefit Management Market, by Service, 2024-2033
9.1.1. Specialty Pharmacy
9.1.1.1. Market Revenue and Forecast (2021-2033)
9.1.2. Retail Pharmacy
9.1.2.1. Market Revenue and Forecast (2021-2033)
10.1. U.S. Pharmacy Benefit Management Market, by End-user, 2024-2033
10.1.1. Commercial
10.1.1.1. Market Revenue and Forecast (2021-2033)
10.1.2. Federal
10.1.2.1. Market Revenue and Forecast (2021-2033)
11.1. U.S.
11.1.1. Market Revenue and Forecast, by Business Model (2021-2033)
11.1.2. Market Revenue and Forecast, by Service (2021-2033)
11.1.3. Market Revenue and Forecast, by End-user (2021-2033)
12.1. CVS Health
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. Cigna
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. Optum, Inc.
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. MedImpact
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. Anthem
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. Change Healthcare
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. Prime Therapeutics LLC
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. HUB International Limited.
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. Elixir Rx Solutions LLC
12.9.1. Company Overview
12.9.2. Product Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
12.10. Abbott
12.10.1. Company Overview
12.10.2. Product Offerings
12.10.3. Financial Performance
12.10.4. Recent Initiatives
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
14.1. About Us
14.2. Glossary of Terms
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Report Description
Get a Sample